Abstracts Archive - Page 2198 of 2607 - ACR Meeting Abstracts

Abstract Number: 528 • 2014 ACR/ARHP Annual Meeting
Calcium-Calcineurin-NFAT Signaling Pathway Regulates AQP5 Expression in Primary Salivary Gland Acinar Cells
Shyh-Ing Jang¹, Hwei Ling Ong¹, Indu Ambudkar² and Illias Alevizos³, ¹Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ²NIDCR, MPTB, NIH, Bethesda, MD, ³NIDCR, Bethesda, MD
Background/Purpose Aquaporin (AQP) 5 belongs to a family of small integral membrane proteins which function as a water channels in cells. AQP5 plays a critical…
Abstract Number: 526 • 2014 ACR/ARHP Annual Meeting
A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren’s Syndrome Patients Using RNA-Seq
Alessia Gallo¹, Mayank Tandon², Shyh-Ing Jang³, Ana Paola Cotrim⁴ and Ilias Alevizos⁵, ¹NIH, Bethesda, MD, ²Sjogren's Clinic, NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁴NIDCR, NIH, Bethesda, MD, ⁵Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose Saliva is a biofluid secreted by the salivary glands (SGs) that is critical for the health of the oral cavity. In Sjögren’s Syndrome (SS),…
Abstract Number: 527 • 2014 ACR/ARHP Annual Meeting
Salivary Expression of S100A7/Psoriasin and Oral Damage in Primary Sjögren’s Syndrome and Overlapping Disorders
Francesca Sernissi¹, Chiara Baldini¹, Daniela Martini¹, Leonardo Lorenzini¹, Laura Bazzichi¹, Antonietta Raffaella Maria Sabbatini¹, Giada Marchi¹, Camillo Giacomelli¹, Marta Mosca² and Stefano Bombardieri², ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: S100A7/psoriasin, a 11.4kDa protein belonging to the S100A family of Ca2+-binding proteins, is known to exhibit an antimicrobial activity at skin level, but has…
Abstract Number: 525 • 2014 ACR/ARHP Annual Meeting
The Genetic Basis of Sjögren’s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort
Lindsey A. Criswell¹, Kimberly E. Taylor^2,3, Quenna Wong⁴, David M. Levine⁴, Caitlin McHugh⁴, Cathy Laurie⁴, Kimberly Doheny⁵, Mi Y. Lam⁶, Alan N. Baer⁷, Stephen Challacombe⁸, Yi Dong⁹, Hector Lanfranchi¹⁰, Morten Schiødt¹¹, M. Srinivasan¹², Susumu Sugai¹³, Hisanori Umehara¹⁴, Frederick B. Vivino¹⁵, Zhao Yan¹⁶, Stephen Shiboski¹⁷, Troy Daniels¹⁸, John S. Greenspan⁶, Caroline H. Shiboski⁶ and Sjögren's Syndrome Collaborative Clinical Alliance (SICCA)¹⁹, ¹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴University of Washington, Biostatistics, Seattle, WA, ⁵Center for Inherited Disease Research, Baltimore, MD, ⁶Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Kings College London, London, United Kingdom, ⁹Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, ¹⁰University of Buenos Aires, Buenos Aires, Argentina, ¹¹Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ¹²Aravind Eye Hospital, Madurai, India, ¹³Kanazawa Medical University, Ishikawa, Japan, ¹⁴Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ¹⁵Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁷Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, ¹⁸Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁹University of California San Francisco, San Francisco, CA
Background/Purpose Our goal is to define the contribution of genetic factors to two hallmark manifestations of SS, keratoconjunctivitis sicca (KCS) and focal lymphocytic sialadenitis (FLS),…
Abstract Number: 524 • 2014 ACR/ARHP Annual Meeting
Distinct Patterns of DNA Methylation in Labial Salivary Gland Tissue Based on Sjögren’s Syndrome Disease Status
Michael Cole¹, Xiaorong Shao¹, Diana Quach², Hong L. Quach², Lisa F. Barcellos² and Lindsey A. Criswell³, ¹Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ²Epidemiology, University of California, Berkeley, Berkeley, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s Syndrome (SS, OMIM #270150) is a chronic, multi-system autoimmune disease characterized by progressive destruction of the exocrine glands, with subsequent mucosal and conjunctival…
Abstract Number: 523 • 2014 ACR/ARHP Annual Meeting
Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
Rosaria Irace¹, Antonella Riccardi¹, Daniela Iacono¹, Luciana Pellecchia¹, Lucia Vicedomini¹, Gabriele Valentini² and Serena Vettori¹, ¹Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Second University of Naples, Napoli, Italy
Background/Purpose CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine. We aimed to investigate CXCL4 serum levels in primary Sjögren’s syndrome (pSS) and looked for associations…
Abstract Number: 522 • 2014 ACR/ARHP Annual Meeting
Whole Blood microRNA Signature for Primary Sjögren’s Syndrome-Related Lymphoma
Jessica Tarn¹, Simon Cockell², Colin Gillespie³, Shereen Al-Ali^1,4, Katherine James¹, James Locke¹, Simon Bowman⁵, Bridget Griffiths⁶, David Young¹ and Wan-Fai Ng⁷, ¹Newcastle University, Newcastle upon Tyne, United Kingdom, ²Bioinformatics Support Unit, Newcastle University, Newcastle upon Tyne, United Kingdom, ³School of Mathematics & Statistics, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴College of Science, University of Basrah, Basrah, Iraq, ⁵Rheumatology Dept (Selly Oak), University Hospital Birmingham, Birmingham, United Kingdom, ⁶Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ⁷Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose Micro RNAs (miRNAs) are 18-25nt non-coding RNAs that bind target/complementary sequences within the 3’UTR of RNA molecules steering them towards degradation or translational repression,…
Abstract Number: 521 • 2014 ACR/ARHP Annual Meeting
CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren ’s Syndrome Patients
Gaetane Nocturne¹, Olivier Fogel², Philippe Dieude³, Jean Jacques Dubost⁴, Anne-Laure Fauchais⁵, Vincent Goeb⁶, Eric Hachulla⁷, Claire Larroche⁸, Véronique Le Guern⁹, Jacques Morel¹⁰, Aleth Perdriger¹¹, Xavier Puéchal¹², Stephanie Rist Bouillon¹³, Valerie Devauchelle¹⁴, Damien Sène¹⁵, O Vittecoq¹⁶, Corinne Miceli-Richard¹⁷, Jacques Gottenberg¹⁸ and Xavier Mariette¹⁹, ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁴Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rhumatology Department, University Hospital, AMIENS, France, ⁷Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁸Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ⁹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹¹Rhumatologie, Rennes, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹³Rhumatologie, Hopital La Source, La Source, France, ¹⁴Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ¹⁵Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁶Rouen University Hospital & Inserm U905, Rouen, France, ¹⁷Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ¹⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications associated with pSS. It affects 5-10% of the patients. Definition of predictive…
Abstract Number: 520 • 2014 ACR/ARHP Annual Meeting
Genetic Variant and High Levels of CCL11 in Serum Are Associated with the Occurrence of Lymphoma and Disease Activity in Primary Sjögren’s Syndrome Patients (pSS)
Gaetane Nocturne¹, Olivier Fogel², Joanne Nititham³, Kimberly E. Taylor⁴, Philippe Dieude⁵, Jean Jacques Dubost⁶, Anne-Laure Fauchais⁷, Vincent Goëb⁸, Eric Hachulla⁹, Claire Larroche¹⁰, Véronique Le Guern¹¹, Jacques Morel¹², Aleth Perdriger¹³, Xavier Puéchal¹⁴, Stephanie Rist Bouillon¹⁵, Alain Saraux¹⁶, Damien Sène¹⁷, Olivier Vittecoq¹⁸, Lindsey A. Criswell¹⁹, Corinne Miceli-Richard²⁰, Jacques Gottenberg²¹ and Xavier Mariette²², ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³University of California San Francisco, 374 Parnassus Avenue, San Francisco, CA, ⁴Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁸Rheumatology, Amiens University Hospital, Amiens, France, ⁹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ¹⁰Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹³Rhumatologie, Rennes, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁵Rhumatologie, Hopital La Source, La Source, France, ¹⁶CHU Brest and EA 2216, UBO, Brest, France, ¹⁷Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁸Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²⁰Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ²¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications of pSS. It occurs in 5-10% of the patients. A more accurate…
Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study
Boulos Haraoui¹, Gustavo Casado², Elke Theander³, Laszlo Czirják⁴, Andrew Taylor⁵, Peter Button⁶, Lykke Hinsch Gylvin⁷ and Roberto Caporali⁸, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Hospital Militar Central, Buenos Aires, Argentina, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴University of Pécs, Pécs, Hungary, ⁵Royal Perth Hospital, Perth, Australia, ⁶Roche Products Pty Limited, Dee Why, Australia, ⁷F. Hoffmann-La Roche, Basel, Switzerland, ⁸Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
Abstract Number: 539 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Lluís Puig Sanz², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Yin You⁵, Yuhua Wang⁵, Alan M. Mendelsohn⁶, Michael Song⁵, Proton Rahman⁷ and Iain B. McInnes⁸, ¹University of California San Diego, La Jolla, CA, ²Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁸University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-23 may be implicated in spondylitis. A substantial number of pts with spondylitis and peripheral joint involvement were enrolled in PSUMMIT. We evaluated the…
Abstract Number: 538 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Atul A. Deodhar¹, Dominique L. Baeten², Jürgen Braun³, Xenofon Baraliakos³, Joachim Sieper⁴, Maxime Dougados⁵, Paul Emery⁶, Brian Porter⁷, Ruvie Martin⁷, Shephard Mpofu⁸ and Hanno Richards⁹, ¹Oregon Health and Sciences University, Portland, OR, ²Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Descartes University, Cochin Hospital, Paris, France, ⁶University of Leeds, Leeds, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ankylosing spondylitis (AS) can have a profound negative effect on an individual's physical functioning, health status and quality of life (QoL), affecting the ability…
Abstract Number: 537 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
Alice B. Gottlieb¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, Peter Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Tufts Medical Center, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has…
Abstract Number: 536 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing
Joachim Sieper¹, Jürgen Braun², Xenofon Baraliakos², Dominique L. Baeten³, Maxime Dougados⁴, Paul Emery⁵, Atul A. Deodhar⁶, Brian Porter⁷, Mats Andersson⁸, Shephard Mpofu⁸ and Hanno Richards⁹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁵University of Leeds, Leeds, United Kingdom, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Previous data indicate that interleukin (IL)-17, a key pro-inflammatory cytokine, might play a role in the pathogenesis of ankylosing spondylitis (AS). We assessed the…
Abstract Number: 504 • 2014 ACR/ARHP Annual Meeting
Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries
Axel Finckh¹, David Neto², M. Victoria Hernández³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhao⁶, K Pavelka⁷, Carl Turesson⁸, Xavier Mariette⁹, Merete Lund Hetland¹⁰ and Jacques Gottenberg¹¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²University of Geneva, Geneva, Switzerland, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ⁷Institute of Rheumatology, Prague, Czech Republic, ⁸Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁰DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose Some observations have suggested that the effectiveness of abatacept (ABA) may be decreased in rheumatoid arthritis (RA) patients (pts) who previously failed rituximab (RTX).(1)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].